Roche announced positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys (delandistrogene moxeparvovec), the first approved gene ...
Roche also reported that no new safety concerns were identified, reinforcing Elevidys's consistent and manageable safety profile observed to date. This article was generated with the support of AI ...
UBS has upgraded Roche ( OTCQX:RHHBY) to buy from neutral, citing the company's growth outlook. "We see sustained outperformance of Vabysmo and Ocrevus as key drivers of near-term growth, with ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene moxeparvovec) in children with the rare muscle-wasting disorder Duchenne ...
Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.
Additionally, the potential benefits from Xolair for food allergies and possible gains from Elevidys outside the United States contribute to the positive outlook. UBS's forecasts for Roche's ...
Sarepta is responsible for regulatory approval and commercialization of Elevidys in the U.S., as well as manufacturing. Roche is responsible for regulatory approvals and bringing Elevidys to ...
As part of a collaboration agreement signed in 2019, Sarepta is working with Roche Holdings AG RHHBY. Sarepta is responsible for regulatory approval and commercializing Elevidys in the U.S. and ...
Roche Holding AG released its Q4 and full-year ... The likes of gene therapy (for Duchenne Muscular Dystrophy, “DMD”), Elevidys, Lymphoma meds Columvi and Itovebi, and Piasky, developed ...